Table 1 Summary of cohort, tumour, treatment and reference standard characteristics of studies included in the individual patient data analysis
Study level estimates | ||||
|---|---|---|---|---|
Variable | Patients (%) | Median | IQR | Range |
Cohort characteristics | ||||
N patients with MRI (8 studies) | 300 (NA) | 36 | 28 – 50 | 13 – 59 |
Recruitment mid-point (year) (4 studies) | 144 (NA) | 2003 | 2001 – 2005 | 2001 – 2006 |
Age, mean or median (years) (8 studies) | 300 (NA) | 47 | 46 – 48 | 43 – 49 |
Menopausal status (%)a (2 studies) | ||||
Pre | 51 (72.9) | 64.6 | 60.4 – 68.8 | 60.4 – 68.8 |
Peri/post | 19 (27.1) | 25.0 | 18.8 – 31.2 | 18.8 – 31.2 |
Tumour characteristics | ||||
Clinical size, mean or median (cm)a (4 studies) | 136 (NA) | 4.6 | 4.2 – 6.6 | 4.0 – 8.2 |
T stage (%)a (4 studies) | ||||
T1 | 5 (2.9) | 2.9 | 1.0 – 5.0 | 0.0 – 6.2 |
T2 | 62 (35.8) | 43.0 | 23.9 – 50.3 | 6.2 – 56.2 |
T3 | 78 (45.1) | 43.6 | 38.3 – 49.1 | 37.5 – 50.0 |
T4 | 28 (16.2) | 9.8 | 0.0 – 30.6 | 0.0 – 41.7 |
Stage (%)a (6 studies) | ||||
I | 1 (0.5) | 0.0 | 0.0 – 0.0 | 0.0 – 3.1 |
II | 131 (59.0) | 66.1 | 45.0 – 78.0 | 27.1 – 86.7 |
III | 83 (37.4) | 32.3 | 22.0 – 37.5 | 0.0 – 72.9 |
IV | 7 (3.2) | 0.0 | 0.0 – 0.0 | 0.0 – 17.5 |
Histology (%)a (6 studies) | ||||
IDC | 191 (84.1) | 86.2 | 74.2 – 87.8 | 68.8 – 90.0 |
ILC or IDC/ILC | 19 (8.4) | 9.8 | 5.1 – 10.0 | 4.9 – 18.8 |
Other | 17 (7.5) | 7.9 | 4.0 – 12.5 | 0.0 – 16.1 |
Nodal status (%)a (4 studies) | ||||
Positive | 109 (72.2) | 71.0 | 62.5 – 80.6 | 56.2 – 87.8 |
Negative | 42 (27.8) | 29.0 | 19.4 – 37.5 | 12.2 – 43.8 |
ER (%)a (5 studies) | ||||
Positive | 113 (60.1) | 62.5 | 60.0 – 64.4 | 45.0 – 69.2 |
Negative | 73 (38.8) | 37.5 | 32.2 – 40.0 | 15.4 – 55.0 |
Unknown or NR | 2 (1.1) | 0.0 | 0.0 – 0.0 | 0.0 – 3.4 |
PR (%)a (4 studies) | ||||
Positive | 71 (44.9) | 41.2 | 32.9 – 49.8 | 30.8 – 52.1 |
Negative | 84 (53.2) | 51.5 | 47.5 – 59.4 | 48.5 – 65.0 |
Unknown or NR | 3 (1.9) | 1.0 | 0.0 – 2.7 | 0.0 – 3.4 |
HER2 (%) (3 studies) | ||||
Positive | 42 (28.8) | 29.2 | 22.5 – 33.9 | 22.5 – 33.9 |
Negative | 97 (66.4) | 62.5 | 61.0 – 77.5 | 61.0 – 77.5 |
Unknown or NR | 7 (4.8) | 5.1 | 0.0 – 8.3 | 0.0 – 8.3 |
Treatment | ||||
NAC regimen (%)a (8 studies) | ||||
Anthracycline-based | 115 (38.1) | 9.3 | 0.0 – 77.6 | 0.0 – 100.0 |
Antracycline-taxane-based | 181 (59.9) | 88.1 | 17.4 – 100.0 | 0.0 – 100.0 |
Other | 6 (2.0) | 0.0 | 0.0 – 2.5 | 0.0 – 100.0 |
Trastuzumab (%)a (3 studies) | ||||
Trastuzumab used | 29 (19.6) | 7.3 | 2.1 – 42.4 | 2.1 – 42.4 |
Trastuzumab not used | 119 (80.4) | 92.7 | 57.6 – 97.9 | 57.6 – 97.9 |
Type of surgery (%)a (8 studies) | ||||
BCS | 132 (43.1) | 50.3 | 37.6 – 55.9 | 6.2 – 59.4 |
Mastectomy | 172 (56.2) | 57.2 | 44.1 – 63.8 | 34.4 – 93.8 |
No surgery | 2b (0.7) | 0.0 | 0.0 – 0.0 | 0.0 – 6.2 |
Reference standard | ||||
Type of reference standard (%) (8 studies) | ||||
Pathology | 298 (99.3) | 100.0 | 100.0 – 100.0 | 93.8 – 100.0 |
Other | 2b (0.7) | 0.0 | 0.0 – 0.0 | 0.0 – 6.2 |
Time from MRI to surgery, mean or median/estimate (days) (6 studies) | 228 (NA) | 16 | 12 – 25 | 7 - 28 |
Prevalence of pCR (%) (8 studies) | 300 (NA) | 19.0 | 15.5 – 23.4 | 7.1 – 27.5 |